|
|
|
|
|
by Amygaz
2351 days ago
|
|
I don’t know what problem that would solve. Academia rarely does trials that end up killing people. Unlike the whole CAR-T cell therapy. Companies like Juno killed almost 50% of their patient, before the FDA halted their trial, which was allowed to resume later, and kill more people. Granted they where going to die anyway. Still the like of Hans Bishop who us held as a hero in the industry because he sold his company for billions, while the product will never be approved. Even if were to be, it would sit on a shelf because it’s too expensive. So much for transparency... (Edited some typos) |
|
This is high stakes medicine, yet the current environment has the docs on this floor terrified of doing anything that isn’t in the standard of care runbook. My wife has had elevated blood glucose levels for six months, which is not good when you’re fighting cancer, yet i can’t get anyone to treat it because there’s no clinical evidence that managing glucose levels for her specific type of cancer has any benefit.
Guess what. Nobody’s doing that trial any time soon. Meanwhile there are thousands of diabetics managing their blood glucose while fighting cancer and there is endless material available demonstrating that cancer cells thrive in hyperglycemic environments.
So, i don’t know anything about Juno, they could be sociopaths. But i have no issues with high risk attempts as long as the patients are informed and there are ethical standards for transparency. At least they are trying.